Skip to main content
NIH Intramural Research Program, Our Research Changes Lives

Navigation controls

  • Search
  • Menu

Social follow links

  • Podcast
  • Instagram
  • Twitter
  • YouTube
  • LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
      • Nobel Prize
      • Lasker Award
      • Breakthrough Prize
      • Shaw Prize
      • Presidential Early Career Award for Scientists and Engineers (PECASE)
      • Presidential Medal of Freedom
      • National Medal of Science
      • Searle Scholars
      • The National Academy of Sciences
      • The National Academy of Medicine
      • The National Academy of Engineering
      • The American Academy of Arts and Sciences
      • National Medal of Technology & Innovation
      • Samuel J. Heyman Service to America Medals
      • Crafoord Prize
      • Fellows of the Royal Society
      • Canada Gairdner Awards
    • Organization & Leadership
    • Our Programs
      • NCI
      • NEI
      • NHGRI
      • NHLBI
      • NIA
      • NIAAA
      • NIAID
      • NIAMS
      • NIBIB
      • NICHD
      • NIDA
      • NIDCD
      • NIDCR
      • NIDDK
      • NIEHS
      • NIMH
      • NIMHD
      • NINDS
      • NINR
      • NLM
      • CC
      • NCATS
      • NCCIH
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
      • Biomedical Engineering & Biophysics
      • Cancer Biology
      • Cell Biology
      • Chemical Biology
      • Chromosome Biology
      • Clinical Research
      • Computational Biology
      • Developmental Biology
      • Epidemiology
      • Genetics & Genomics
      • Health Disparities
      • Immunology
      • Microbiology & Infectious Diseases
      • Molecular Biology & Biochemistry
      • Molecular Pharmacology
      • Neuroscience
      • RNA Biology
      • Social & Behavioral Sciences
      • Stem Cell Biology
      • Structural Biology
      • Systems Biology
      • Virology
    • Principal Investigators
      • View by Investigator Name
      • View by Scientific Focus Area
    • Accomplishments
      • View All Accomplishments by Date
      • View All Health Topics
      • The Body
      • Health & Wellness
      • Conditions & Diseases
      • Procedures
    • Accelerating Science
      • Investing in Cutting-Edge Animal Models
      • Creating Cell-Based Therapies
      • Advancing Computational and Structural Biology
      • Combating Drug Resistance
      • Developing Novel Imaging Techniques
      • Charting the Pathways of Inflammation
      • Zooming in on the Microbiome
      • Uncovering New Opportunities for Natural Products
      • Stimulating Neuroscience Research
      • Pursuing Precision Medicine
      • Unlocking the Potential of RNA Biology and Therapeutics
      • Producing Novel Vaccines
    • Research in Action
      • View All Stories
      • Battling Blood-Sucking Bugs
      • Unexpected Leads to Curb Addiction
      • Shaping Therapies for Sickle Cell Disease
      • The Mind’s Map Maker
    • Trans-IRP Research Resources
      • Supercomputing
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
      • Get Involved with Clinical Research
      • Physician Resources
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
      • Stadtman Tenure-Track Investigators
        • Science, the Stadtman Way
      • Lasker Clinical Research Scholars
      • Independent Research Scholar
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
I am Intramural Blog

Orloff Science Awards Recognize Aplastic Anemia Treatment

By IRP Staff Blogger

Tuesday, March 8, 2016

Reblogged from the NHLBI Intranet (NIH-only access). Originally posted on March 2, 2016.

Congratulations to the Orloff Science Awards recipients of 2015! These awards both celebrate and highlight extraordinary scientific achievements and technical advancements of scientific research and innovation conducted in the Intramural Research Program of the National Heart, Lung, and Blood Institute (NHLBI) at NIH.

From genetic studies to pharmacology, the Orloffs honor the remarkable work and responsibilities our researchers undertake every day to make a difference in the world—science that truly matters and impacts human health. These prestigious awards are selected by NHLBI Scientific Director Dr. Robert Balaban and Director Dr. Gary Gibbons based on the compelling nature of their stories and scientific impact.

Dr. Balaban began this year’s award ceremony with his opening remarks and surprised the audience with a visit from Dr. Richard Childs via teleconference from Liberia, where he narrated a slideshow highlighting the incredible work of the Public Health Service (PHS) in fighting Ebola. Presentations given by a member of each Orloff award team followed to highlight the teamwork found within DIR to make these scientific advances.

Because each award team has a truly unique research focus and method, there will be a series of blogs highlighting their achievements to share their stories. This post is the first of many to come!

The first team to be featured was recognized for laboratory and clinical research resulting in FDA approval of the thrombopoietin agonist eltrombopag as the first new treatment for aplastic anemia in three decades. This team was led by Dr. Cynthia Dunbar, who presented the work at the ceremony.

Research contributors: Dr. Neal Young, Dr. Matthew Olnes, Dr. Ronan Desmond, Dr. Thomas Winkler, Dr. Danielle Townsley, Dr. Bogdan Dumitriu, Dr. Andre Larochelle, Ms. Brenda Fitzsimmons, Ms. Susan Soto, Ms. Kinneret Broder, Ms. Marlene Peters Lawrence, Ms. Diane Madey, Ms. Olga Rios, Ms. Barbara Weinstein, Mr. Vince Williams, Ms. Cecilia Pazman, Ms. Judy Starling, Ms. Laura Broe, Ms. Stephanie Sellers, Dr. Katherine Calvo, Dr. Phillip Scheinberg, Dr. Colin Wu, Dr. Angelique Biancotto, Dr. Xingmin Feng, Dr. Jay Lozier, Dr. Margaret Bevans, Ms. Janet Valdez, Dr. Yong Tang, Mrs. Marie Desierto

Signs of New Discovery

Since the approval of the ATG/CSA (intensive immunosuppressive treatment) for aplastic anemia in the 1980s, and despite numerous clinical trials studying candidate drugs and new combination regimens, no new effective treatment has been identified for this devastating illness until now.

Dr. Dunbar presents on her team's research at the 2015 Orloff Science Awards

Aplastic anemia (AA) is a blood disorder in which the body’s bone marrow is deficient in stem cells and cannot make enough new blood cells, resulting in bleeding, infections, and fatigue. Based on years of laboratory investigation and a series of landmark clinical trials initiated in 2009, Drs. Dunbar and Neal Young have discovered an effective new treatment for aplastic anemia.

Patients with severe refractory AA, unresponsive to multiple prior therapies and ineligible for bone marrow transplant, were enrolled in the initial trial. Almost half responded, most with normalization of their blood counts in all cell lineages. This highly effective treatment involving a single daily dose of a well-tolerated oral medication showed a robust pattern of response. Patients were even able to discontinue the drug after months to years of treatment and maintain responses, indicating that the drug had effectively expanded hematopoietic stem cells. This is the first evidence in history for successful pharmacologic stem cell expansion in vivo in humans.

Following the results of these clinical trials, the FDA invited GlaxoSmithKline (a global healthcare company) to work with the NHLBI team in submitting a new labeling application for the use of eltrombopag in aplastic anemia. This relabeling was critical to allow patients to receive insurance reimbursement for this expensive drug and to instruct prescribers on the correct dosing for eltromobpag and the expected kinetics of response, which differed significantly from the initial labeling of eltrombopag for use in immune thrombocytopenia (ITP). The FDA approved the drug in August 2014, and a similar approval package was submitted to the European Commission in November 2014 and is undergoing review.

Life Changing Success for Patients

If an individual’s bone marrow cannot make enough new blood cells, many health problems can occur due to a lack of platelets (bleeding), neutrophils (infections), and red blood cells (fatigue, heart failure, and shortness of breath). Untreated or unresponsive severe aplastic anemia often results in death.

Suffering from this debilitating condition and failing multiple prior therapies, a young woman separated from her children and hospitalized at the NIH repeatedly for life-threatening infections and bleeding has finally been able to rejoin her family again because of this treatment. Another young man, unable to work because of complications, had suffered years of multiple intensive and toxic prior therapies, multiple hospitalizations for infections and bleeding, and had been transfusion-dependent for twice weekly platelet transfusions and bi-weekly red blood cells. For the first time in 15 years, he has normalized his counts, discontinued transfusions and has begun working again and living a normal life.

The lives of aplastic anemia patients have been changed by the work of Drs. Dunbar and Young and their team members. Not only is this the first effective new treatment for aplastic anemia in three decades, but obtaining FDA approval and relabeling this drug based on an investigator-sponsored small phase 2 trial in this era of billion dollar pharmaceutical company clinical research is considered unprecedented. Congratulations again to Drs. Dunbar and Young for leading their research team to make this incredible achievement!

Watch Dr. Dunbar discuss the science for which she won the award in this video.


Category: IRP Discoveries
Tags: aplastic anemia, eltrombopag, clinical trials, pharmacology, Orloff Science Award, FDA approval, treatment, medicine, blood transfusion, blood cells, Clinical Center, immune thrombocytopenia

Related Blog Posts

  • Unlocking the Genetic Mysteries of Rare Autoinflammatory Diseases
  • IRP’s Cynthia Dunbar Elected to National Academy of Medicine
  • Inflammation Cuts Lifeline for Blood-Producing Stem Cells
  • Helping the Heart Stand Up to Sepsis
  • Bone Marrow Cells Reveal Secret Weapon to Battle Bacteria

This page was last updated on Wednesday, January 31, 2024

Blog menu

  • Contributing Authors
    • Anindita Ray
    • Brandon Levy
    • Devon Valera
    • Melissa Glim
  • Categories
    • IRP Discoveries
    • Profiles
    • Events
    • NIH History
    • IRP Life

Blog links

  • Subscribe to RSS feed

Get IRP Updates

Subscribe

  • Email
  • Print
  • Share Twitter Facebook LinkedIn

Main navigation

  • About Us
    • What Is the IRP?
    • History
    • Honors
    • Organization & Leadership
    • Our Programs
    • Research Campus Locations
    • Contact Information
  • Our Research
    • Scientific Focus Areas
    • Principal Investigators
    • Accomplishments
    • Accelerating Science
    • Research in Action
    • Trans-IRP Research Resources
    • IRP Review Process
    • Commercializing Inventions
  • NIH Clinical Center
    • Clinical Center Facilities
    • Clinical Faculty
    • Advancing Translational Science
    • Clinical Trials
  • News & Events
    • In the News
    • I am Intramural Blog
    • Speaking of Science Podcast
    • SciBites Video Shorts
    • The NIH Catalyst Newsletter
    • Events
  • Careers
    • Faculty-Level Scientific Careers
    • Trans-NIH Scientific Recruitments
    • Scientific & Clinical Careers
    • Administrative Careers
  • Research Training
    • Program Information
    • Training Opportunities
    • NIH Work/Life Resources
  • Department of Health and Human Services
  • National Institutes of Health
  • USA.gov

Footer

  • Home
  • Contact Us
  • IRP Brand Materials
  • HHS Vulnerability Disclosure
  • Web Policies & Notices
  • Site Map
  • Search